Continuous high dosing of lenalidomide in relapsed, refractory or older newly diagnosed acute myeloid leukemia patients not suitable for other treatment options - results from a phase I study

Lenalidomideis an immunomodulatory drugapproved for multiple myeloma, relapsed mantle cell lymphomaand myelodysplastic syndrome(MDS) with deletion of chromosome 5q (del(5q)). Based on the high rate of hematologic improvement and cytogeneticresponses seen in del(5q) MDS, several trials have been